Atorlip 20 contains atorvastatin, a potent lipid-lowering medication trusted by healthcare professionals worldwide. It is indicated as an adjunct to diet and lifestyle modifications to significantly reduce elevated LDL cholesterol and triglyceride levels in the blood. By inhibiting HMG-CoA reductase, it plays a crucial role in primary and secondary prevention of cardiovascular events. This medication is suitable for adults requiring moderate-intensity statin therapy under medical supervision.

Features

• Active ingredient: Atorvastatin Calcium 20 mg
• Pharmaceutical form: Film-coated tablets
• Mechanism: Selective, competitive inhibitor of HMG-CoA reductase
• Bioavailability: Approximately 12%
• Protein binding: ≥98%
• Metabolism: Hepatic via CYP3A4
• Elimination half-life: Approximately 14 hours
• Excretion: Primarily via bile; <2% renal excretion

Benefits

• Significantly reduces LDL cholesterol levels by 40-50% with 20 mg daily dose
• Lowers risk of myocardial infarction, stroke, and revascularization procedures
• Increases HDL cholesterol while reducing triglycerides
• Provides anti-inflammatory effects independent of lipid-lowering
• Stabilizes existing atherosclerotic plaques
• Improves endothelial function and reduces oxidative stress

Common use

Atorlip 20 is primarily prescribed for hypercholesterolemia, including heterozygous and homozygous familial hypercholesterolemia. It is indicated for patients who have not achieved target LDL levels through diet and exercise alone. The medication is also used in mixed dyslipidemia and for primary prevention in patients with multiple risk factors. Clinical evidence supports its use in slowing the progression of coronary atherosclerosis and reducing cardiovascular morbidity and mortality.

Dosage and direction

The recommended starting dose is 20 mg once daily, which may be adjusted based on lipid response and tolerability. Administration can occur at any time of day, with or without food, though consistency in timing is advised. Dosage adjustments should occur at 2-4 week intervals, not exceeding 80 mg daily. For patients taking concomitant CYP3A4 inhibitors, dose reduction may be necessary. Renal impairment typically doesn’t require adjustment, while hepatic impairment necessitates caution.

Precautions

Liver function tests must be performed before initiation and periodically during treatment. Patients should report unexplained muscle pain, tenderness, or weakness immediately. Blood glucose levels should be monitored as hyperglycemia may occur. Use with caution in patients consuming substantial quantities of alcohol or with history of liver disease. Elderly patients may require closer monitoring due to potential for increased systemic exposure. Pregnancy and breastfeeding are absolute contraindications.

Contraindications

Active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. Hypersensitivity to any component of this medication. Pregnancy, lactation, and women of childbearing potential not using adequate contraception. Concomitant use with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, HIV protease inhibitors, or clarithromycin.

Possible side effects

Common adverse reactions (≥2%) include headache, myalgia, arthralgia, nausea, diarrhea, and constipation. Musculoskeletal effects may progress to myopathy or rhabdomyolysis in rare cases. Elevated liver enzymes occur in 0.7% of patients. Other reported effects include insomnia, nightmares, and cognitive impairment. Gastrointestinal disturbances typically resolve with continued therapy. Rare cases of immune-mediated necrotizing myopathy have been reported.

Drug interaction

Strong CYP3A4 inhibitors significantly increase atorvastatin exposure. Cyclosporine, gemfibrozil, and niacin increase myopathy risk. Oral contraceptives containing ethinyl estradiol and norethindrone show increased AUC. Digoxin levels may increase moderately. Colchicine coadministration requires careful monitoring for myopathy. Warfarin may show enhanced anticoagulant effect requiring INR monitoring. Antacids containing magnesium and aluminum hydroxide decrease atorvastatin absorption.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for the missed one. Maintain regular dosing schedule. Consistent daily administration provides optimal lipid-lowering effects. If multiple doses are missed, consult healthcare provider before resuming therapy.

Overdose

No specific antidote exists for atorvastatin overdose. Supportive measures should be implemented with attention to symptomatic treatment. Gastric lavage may be considered if presented early. Liver function and CPK levels should be monitored. Hemodialysis is not expected to enhance elimination due to extensive protein binding. Cases of overdose have reported elevated liver enzymes and muscle effects.

Storage

Store at room temperature (15-30°C) in original container protected from light and moisture. Keep tightly closed and away from excessive heat. Do not store in bathroom or damp places. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Proper disposal of unused medication should follow local regulations.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult qualified healthcare providers for diagnosis and treatment decisions. Individual response to medication may vary. Do not initiate or discontinue therapy without medical supervision. Full prescribing information should be reviewed before use.

Reviews

Clinical studies demonstrate Atorlip 20’s efficacy in reducing LDL cholesterol by 43-50% from baseline. The ASCOT-LLA trial showed 36% reduction in non-fatal MI and fatal CHD. SPARCL trial demonstrated 16% relative risk reduction in stroke. Real-world evidence supports long-term safety profile with appropriate monitoring. Patient satisfaction surveys indicate good tolerability and adherence rates compared to other statins.